FOR IMMEDIATE RELEASE Contacts: PRESS RELEASE Exhibit 99.1 GLOBAL PARTNERS LP 800 South Street, Suite 500 P.O. Box 9161 Waltham, MA 02454-9161 www.globalp.com Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners Reports Third-Quarter 2024 Financial Results Waltham, Mass., November 8, 2024 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for ...

Though the stock market has raced to fresh all-time highs over the past month, the mood is anything but complacent as we head toward a potentially fractious election amid an uncertain macroeconomy. And one of the most volatileWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor on S ...

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in patients with diabetes Phase II study (COVALENT-211), combining icovamenib with a GLP-1-based therapy, planned to begin in 2025 BMF-650, an investigational next-generation, oral small-molecule GLP-1 receptor agonist (GLP-1 RA), demonstrated positive early ...

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star. One of the biggest sensations fueling the healthcare space right now is the medication class of glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with the term "GLP-1," you've probably heard of Ozempic and Wegovy. Both medications are GLP-1 agonists, used to treat diabetes and obesity, respectively. These treatments have become blockbuster drugs for their mak ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024. This is an important outcome because it now leads to another milestone for investors to look forward to, which is the initiation of the 36-week phase 2b study using this drug to treat these patients in Q4 of 2024. The scope of this biotech though is its ability to achieve rapid weight loss in a short amount of time a ...

Novartis is taking a more calculated and strategic approach to its growth. There are $200 billion reasons healthcare companies want to produce GLP-1 weight loss drugs. At that size, the market potential is huge, and the opportunities for revenue growth are plentiful. But it also means that competition will be fierce. And with some highly effective treatments already approved and available, the bar is set high for any new drug that wants to take a slice of that lucrative market. Not every company is jumping ...

Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With over 1.2 million patients, Wisp Now Also Bolsters its Menopause Solutions, Empowering Women Through All Major Stages of ...

The future of the weight loss market might not revolve around GLP-1 drugs. By now, nearly everyone has heard of the weight loss drugs targeted at the glucagon-like protein 1 (GLP-1) receptor, like Zepbound and Wegovy by Eli Lilly and Novo Nordisk, respectively. It's no surprise why they're household names; those medicines are bringing in billions of revenue every quarter, driving share prices up relentlessly along the way. However, GLP-1-based therapies aren't going to be the only option in the weight loss ...

GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York Stock Exchange. The merger includes GCP's international operations in Japan, the United States, Europe, Brazil, and Vietnam. The transaction is valued at a total of $5.2 billion, which consists of an initial consideration of $3.7 billion and a potential additional payout of up to $1.5 billion tied to performanc ...